A regulatory effect of arginine vasopressin (AVP) on sweat water conservation has been 41 hypothesized but not definitively evaluated. AVP-mediated insertion of sweat and salivary gland 42 aquaporin-5 (AQP5) water channels through activation of the vasopressin type 2 receptor (V2R) 43 remains an attractive, yet unexplored, mechanism that could result in a more concentrated 44 sweat with resultant decreased water loss. Ten runners participated in a double-blind 45 randomized control treadmill trial under three separate pharmacologic conditions: a placebo; 46 V2R agonist (0.2mg desmopressin); or V2R antagonist (30mg tolvaptan). After a familiarization 47 trial, runners ran for 60 minutes at 60% of peak speed followed by a performance trial to 48 volitional exhaustion. Outcome variables were collected at three exercise time points: baseline, 49 after the steady-state run, and after the performance run. Bodyweight losses were <2% across 50 all three trials. Significant pharmacological condition effects were noted for urine osmolality 51 
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The capability of water reabsorption within an estimated 1.6 to 4.0 million sweat glands (41) is a 77 teleological appealing possibility, which could maximize water conservation during prolonged 78 periods of thermoregulatory stress. Exercise performed at intensities above 50% of VO 2 79 maximum can shift up to 92% of all water (and 87% of all sodium losses) away from urine 80 production towards requisite thermoregulatory sweat production (6; 29; 32). This primary shift in 81 water and sodium excretion routes would be of increasing homeostatic importance during 82 endurance exercise, particularly when performed in hot environments. Thus, the capacity for 83 osmotically-mediated water conservation to occur in sweat glands would be an attractive 84 effector mechanism aimed at maintaining fluid homeostasis during sustained periods of 85 thermoregulatory stress. [AVP] P (7; 33; 34; 45). Therefore, AVP-mediated insertion of AQP5 water channels through 101 activation of the V2R within the apical membrane of the sweat gland remains an enticing, yet 102 unexplored, mechanism. 103 104 AQP5 water channels have been identified within the apical membrane of secretory cells 105 located in salivary, sweat, lacrimal, and airway submucosal glands as well as in corneal, 106 nasopharyngeal, bronchial and uterus epithelium (4; 20; 28; 43). AQP5 channels in sweat duct 107 epithelium have been found in the distal apical tubule segments (4), a location mirroring that of 108 the collecting duct principle cells within the kidney (17). In renal epithelium, collecting duct 109 aquaporin activity is the key step in the final manipulation of urine water loss (17) which further 110 supports the physiological plausibility of a parallel relationship between AVP and AQP activity 111 within sweat gland epithelium. AQP5 water channels appear to be regulated by factors such as 112 tumor necrosis factor α, hypertonic stress, and/or activation of the cyclic adenosine 113 monophosphate second messenger system (43). Progesterone is currently the only known 114 hormonal mediator of AQP5 channel protein expression, as was demonstrated in the epithelial 115 cells of the rat uterus when exposed to progesterone in vivo (20). Whether or not the principle 116 hormone of water homeostasis, AVP, stimulates synthesis or membrane insertion of AQP5water channels has yet to be explored, although the mechanism underlying AVP activation of 118 AQP2 channels via V2R stimulation in response to hypertonic stress has been clearly 119 delineated within the kidney (17). 120
121
This primary aim of this study was to critically assess whether or not sweat water content and 122 sodium concentration are acutely regulated by dynamic changes in AVP acting on the V2R 123 during treadmill running. Secondary aims were to evaluate running performance and core 124 temperature to further characterize the role of AVP in the coordinated balance of fluid and 125 temperature homeostasis during exercise. The potential significance of positive findings could: 126 1) establish a plausible connection between AVP and AQP5 water channel translocation, and 2) 127 revive scientific interest in the primitive sweat gland as an important regulator of fluid and 128 sodium balance during endurance exercise. 129
130

Materials and Methods 131
Participants.Ten healthy (no acute or chronic medical conditions requiring regular prescription 132 medication use), habitual runners (>50km weekly running distance for >6 weeks prior to study 133 participation) between the ages of 18-60 were recruited to participate in this trial. Exclusion 134 criteria were:1) history of kidney problems; 2) inability to sense thirst; 3) difficulty swallowing; 4) 135 history of gastrointestinal disorders; and 5) history of fainting associated with venipuncture. Oral 136 and written informed consent was obtained from each participant before the trial began. This 137 study was approved by both the Oakland University and Georgetown University Medical Center 138
Institutional Review Boards. The study protocol was registered in ClinicalTrials.gov as identifier 139
NCT02084797. 140 141
Experimental Protocol.All consenting participants presented to the exercise lab on four separate 142 occasions, at the same time of day, every other week. Each participant was instructed to refrain 143 from exercise 24 hours immediately preceding and competitive events of >21km within three 144 days of each lab trial. The first lab visit (Trial 1) was a treadmill familiarization trial during which 145 an incremental test to volitional exhaustion was performed to determine each participant's VO 2 146
Peak. This VO 2 Peak test was then utilized in Trials 2, 3, and 4 as the Performance test. 147 Specifically, after a 5 minute warm-up, each participant ran for one minute at a self-selected 148 comfortable speed, equivalent to the average speed of an easy run. Thereafter, the speed on 149 the treadmill was increased by 0.5 miles per hour (mph) every 60 seconds until the participant 150 could no longer keep pace with the treadmill (volitional exhaustion). For the whole body wash-down technique (1; 42), after completion of the performance stage of 255 the trial, each participant was placed in a plastic kiddie pool within a fully-enclosed walk-in tent. 256
With the participant seated in the middle of the pool, one researcher poured approximately 1.5L 257 of distilled water over the participant's head and body. The participant was then asked to 258 remove all clothing in the privacy of the tent and then pour the remaining amount of distilled 259 water (3.78L total) over his or her body, leaving the clothes and the water jug within the pool. 260
The participant was provided a clean towel to dry him or herself off and asked to leave the towel 261 within the kiddie pool. After the participant redressed, the contents of the kiddie pool were 262 swirled around vigorously for 60 seconds and two 1.5mL Eppendorf tubes were filled with 263 samples of water obtained from the contents of the kiddie pool. These whole body wash-down 264 samples were then stored at -80°C until electrolyte analyses could be performed. Sweat ], and osmolality were measured 277 as in the plasma samples. After these sample aliquots were removed and stored, all remaining 278 urine was measured for volume (mL) before being discarded. values. Linear regression analyses (Pearson's) were performed to assess relationships between 296 variables. Statistical significance alpha level was set a priori at p < 0.05. All data presented as 297 mean±SD unless otherwise noted. It was previously estimated that 5-8 participants would 298 provide adequate statistical power (β=0.2) to detect changes in sweat electrolyte concentrations 299 that would exceed the within-participant coefficient of variation based on previous studies (25) . 300
301
Results
302
Ten participants successfully completed the study trial (8 males and 2 females). One female 303
reported regular menses and was tested only during the follicular phase of her cycle while the 304 other female ceased menstruation and was tested every other week, like the male subjects. 305
Since previous pilot testing demonstrated no sex differences in any of the variables of interest 306 Table 1 . 333
334
For fluid balance and exercise performance parameters, one-way ANOVA analyses revealed 335 significant differences in total urine produced and total water ingested, but not in overall water 336 balance, performance time, or plasma volume change (Table 2) ], greater increases were seen during V2R antagonist treatment 347 compared to V2R agonist treatment, but these differences were not statistically significant 348 ( Figure 5B evidenced by urine osmolality values that were higher than the values obtained in either the 362 placebo and V2R antagonist condition at all exercise points tested ( Figure 4B) . Similarly, 363 confirmation of V2R antagonism by the selective V2R antagonist tolvaptan was evidenced by 364 urine osmolality values that were significantly lower than those obtained in either the placebo 365 and V2 agonist condition at all exercise points tested ( Figure 3B ). Blocking the V2R augmented 366 urinary free-water excretion, as verified by a urine volume production that was 3-fold greater 367 than in the placebo and V2R agonist trials ( Table 2 ). The lack of a significant decrease in urine 368 volume with desmopressin treatment likely reflects near-maximal exercise-induced antidiuresis 369 in the placebo state. Thus, the intended activation and blockade of the V2R by the treatment 370 protocols were successfully confirmed by urinary output measures, and particularly highlighted 371 by the changes in urine osmolality ( Figure 4B ). These expected changes in urinary free water 372 excretion, however, were not accompanied by parallel changes in either sweat or salivary 373 secretions. It therefore appears unlikely that V2R activation stimulates AQP5 water channel 374 activity in sweat or salivary glands, in contrast to AVP-mediated V2R activation with subsequent 375 insertion of AQP2 into the lumen of the kidney collecting duct principal cells. 376 V2R effects on AVP secretion were physiologically compensated by osmotically appropriate 378 changes in endogenous AVP secretion (Table 1) . Furthermore, changes in [AVP] P coincided 379 with osmotically appropriate changes in behavioral thirst ratings (Table 1) . Hyperosmolality 380 associated with maximal exercise intensity was likely attributed to the 9-10% decline in plasma 381 volume, as documented previously (50). Of note, hypernatremia (plasma [Na + ] >145mEq/L) was 382 documented in seven athletes after the steady-state and eight athletes after the performance 383 run during the V2R antagonist trial (Figure 2A) . Drinking according to thirst, particularly in the 384 V2R antagonist trial, may have been attenuated by stomach fullness (39) or distraction from 385 completing the assigned treadmill task. The augmented hypernatremia demonstrated in the V2R 386 antagonist condition, however, did not adversely affect overall water balance, body weight 387 change, or performance compared to both the placebo and the V2R agonist conditions (Table  388 2). losses (V2R antagonist condition) were adequately compensated by drinking according to thirst 453 during each study trial. There were no statistically significant differences between fluid balance 454 and %body weight change between the three study conditions ( Table 2) . As expected, fluid 455 intake was greatest during the V2R antagonist condition with total water ingestion approximately 456 50% higher than either the total amount of water ingested during the placebo and V2R agonist 457 condition to compensate for the 3-fold increase in urinary losses (Table 2) . 458 459 V2R effects on core temperature and performance: The only statistically significant difference in 460 peak body temperature was seen between the placebo vs. V2R agonist conditions after the 461 performance time point (38.4°C vs. 38.9°C, respectively). This finding appears to contradict data 462 obtained from rats suggesting that central AVP administration acts as an antipyretic agent, at 463 least in response to fever (31). There was no difference in exercise performance between the 464 three pharmacologic conditions (Table 2 ). However, treadmill running time to exhaustion was 465 extended by 32 seconds (5%) during the V2R antagonist over the placebo trial despite the 466 increased tonicity (hypernatremia) and associated cellular dehydration, which persisted after the 467 steady-state run into the performance test. 468
469
Limitations 470
We utilized both: 1) the customary measurement (sweat patch) and 2) gold standard 471 measurement (WBW) to measure changes in sweat [Na + ] as a primary outcome measure. 472 Nonetheless, our inability to detect subtle, real-time, regulatory changes in sweat gland output 473 remains a study limitation. The difference in urine osmolality between the V2R antagonist 474 versus the placebo and V2R agonist conditions were sufficiently robust, however, to negate 475 even modest measurement errors in the interpretation of our sweat data. Other potential study 476 limitations include lack of control of room temperature, daily exercise, or food intake, all of which 477 could potentially affect the results. 478
Perspectives and significance 480
These data indicate that the V2R does not modulate water losses from sweat or saliva during 481 moderate to high intensity exercise stress. Despite the teleological advantage of reducing sweat 482 water and sodium losses during exercise, this appears not to be a major homeostatic 483 mechanism during acute exercise. The present study used pharmacological manipulation with 484 a receptor-specific agonist and antagonist to activate and inhibit the AVP V2R, thereby 485 overriding the effects of endogenous AVP secretion. As such, these results provide indirect 486 evidence that the V2R does not affect translocation of AQP5 channels that are present in sweat 487 and salivary glands. In contrast, this study verified that V2R activation or blockade produced 488 
